Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1991 Aug;103(4):1946–1950. doi: 10.1111/j.1476-5381.1991.tb12357.x

Measurements of tacrine and monoamines in brain by in vivo microdialysis argue against release of monoamines by tacrine at therapeutic doses.

H A Baldwin 1, R J De Souza 1, G S Sarna 1, T K Murray 1, A R Green 1, A J Cross 1
PMCID: PMC1908181  PMID: 1912982

Abstract

1. The concentration of tacrine (tetrahydroaminoacridine or THA) in plasma, regions of brain and cerebral extracellular fluid has been studied in the rat at various times following injection of a dose of 5 mg kg-1, i.p. 2. The peak plasma THA concentration was 2.46 nmol ml-1, and occurred 30 min post injection and clearance was first order (t1/2 = 90 min). The concentration in the brain peaked between 30-60 min, and was around 30 times plasma concentration (striatum peak concentration = 65 +/- 3 nmol g-1). Extracellular cerebral concentration measured by in vivo microdialysis was similar to plasma concentration with the peak occurring 100 min post-injection. 3. No evidence was obtained by in vivo dialysis for THA inducing dopamine release from striatum or 5-hydroxytryptamine (5-HT) release from the frontal cortex. Enhanced release of dopamine did occur after (+)-amphetamine (5 mg kg-1, i.p.) injection, while KCl (100 mM) in the probe released both dopamine and 5-HT. 4. Since the minimum plasma THA concentration achieved in this study was at least twice that found in the plasma of patients given THA for the treatment of dementia, these results suggest that monoamine release in the brain does not occur during therapy.

Full text

PDF
1946

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Albin R. L., Young A. B., Penney J. B. Tetrahydro-9-aminoacridine (THA) interacts with the phencyclidine (PCP) receptor site. Neurosci Lett. 1988 Jun 7;88(3):303–307. doi: 10.1016/0304-3940(88)90228-5. [DOI] [PubMed] [Google Scholar]
  2. Drukarch B., Kits K. S., Van der Meer E. G., Lodder J. C., Stoof J. C. 9-Amino-1,2,3,4-tetrahydroacridine (THA), an alleged drug for the treatment of Alzheimer's disease, inhibits acetylcholinesterase activity and slow outward K+ current. Eur J Pharmacol. 1987 Sep 2;141(1):153–157. doi: 10.1016/0014-2999(87)90424-9. [DOI] [PubMed] [Google Scholar]
  3. Drukarch B., Leysen J. E., Stoof J. C. Further analysis of the neuropharmacological profile of 9-amino-1,2,3,4-tetrahydroacridine (THA), an alleged drug for the treatment of Alzheimer's disease. Life Sci. 1988;42(9):1011–1017. doi: 10.1016/0024-3205(88)90431-6. [DOI] [PubMed] [Google Scholar]
  4. Forsyth D. R., Ford J. M., Truman C. A., Roberts C. J., Wilcock G. K. Determination of tacrine hydrochloride in human serum by chloroform extraction, reversed-phase high-performance liquid chromatography and fluorimetric detection. J Chromatogr. 1988 Dec 9;433:352–358. doi: 10.1016/s0378-4347(00)80620-9. [DOI] [PubMed] [Google Scholar]
  5. Hunter A. J., Murray T. K., Jones J. A., Cross A. J., Green A. R. The cholinergic pharmacology of tetrahydroaminoacridine in vivo and in vitro. Br J Pharmacol. 1989 Sep;98(1):79–86. doi: 10.1111/j.1476-5381.1989.tb16865.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Hutson P. H., Sarna G. S., Kantamaneni B. D., Curzon G. Monitoring the effect of a tryptophan load on brain indole metabolism in freely moving rats by simultaneous cerebrospinal fluid sampling and brain dialysis. J Neurochem. 1985 Apr;44(4):1266–1273. doi: 10.1111/j.1471-4159.1985.tb08753.x. [DOI] [PubMed] [Google Scholar]
  7. Nielsen J. A., Mena E. E., Williams I. H., Nocerini M. R., Liston D. Correlation of brain levels of 9-amino-1,2,3,4-tetrahydroacridine (THA) with neurochemical and behavioral changes. Eur J Pharmacol. 1989 Nov 28;173(1):53–64. doi: 10.1016/0014-2999(89)90008-3. [DOI] [PubMed] [Google Scholar]
  8. Osterrieder W. 9-Amino-1,2,3,4-tetrahydroacridine (THA) is a potent blocker of cardiac potassium channels. Br J Pharmacol. 1987 Nov;92(3):521–525. doi: 10.1111/j.1476-5381.1987.tb11352.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Palmer A. M., Steele J. E., Lowe S. L., Bowen D. M. Influence of tetrahydro-9-aminoacridine on excitatory amino acid release. Clin Neuropharmacol. 1990 Feb;13(1):58–66. doi: 10.1097/00002826-199002000-00006. [DOI] [PubMed] [Google Scholar]
  10. Robinson T. N., De Souza R. J., Cross A. J., Green A. R. The mechanism of tetrahydroaminoacridine-evoked release of endogenous 5-hydroxytryptamine and dopamine from rat brain tissue prisms. Br J Pharmacol. 1989 Dec;98(4):1127–1136. doi: 10.1111/j.1476-5381.1989.tb12656.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Rogawski M. A. Tetrahydroaminoacridine blocks voltage-dependent ion channels in hippocampal neurons. Eur J Pharmacol. 1987 Oct 6;142(1):169–172. doi: 10.1016/0014-2999(87)90670-4. [DOI] [PubMed] [Google Scholar]
  12. Schauf C. L., Sattin A. Tetrahydroaminoacridine blocks potassium channels and inhibits sodium inactivation in Myxicola. J Pharmacol Exp Ther. 1987 Nov;243(2):609–613. [PubMed] [Google Scholar]
  13. Stevens D. R., Cotman C. W. Excitatory actions of tetrahydro-9-aminoacridine (THA) on hippocampal pyramidal neurons. Neurosci Lett. 1987 Aug 31;79(3):301–305. doi: 10.1016/0304-3940(87)90448-4. [DOI] [PubMed] [Google Scholar]
  14. Summers W. K., Majovski L. V., Marsh G. M., Tachiki K., Kling A. Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. N Engl J Med. 1986 Nov 13;315(20):1241–1245. doi: 10.1056/NEJM198611133152001. [DOI] [PubMed] [Google Scholar]
  15. Whalley L. J. Drug treatments of dementia. Br J Psychiatry. 1989 Nov;155:595–611. doi: 10.1192/s0007125000018079. [DOI] [PubMed] [Google Scholar]
  16. de Belleroche J., Gardiner I. M. Inhibitory effect of 1,2,3,4-tetrahydro-9-aminoacridine on the depolarization-induced release of GABA from cerebral cortex. Br J Pharmacol. 1988 Aug;94(4):1017–1019. doi: 10.1111/j.1476-5381.1988.tb11615.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES